a-galactosylceramide (aGalCer) that is presented by CD1d have been reported to be cytotoxic for myelomonocytic leukemia cells. However, the necessity for leukemia cell CD1d expression, the role of aGalCer, and the cytotoxic mechanisms have not been fully elucidated. We evaluated these issues with myeloid leukemia cells from 14 patients and purified NKT cells that were aGalCer/CD1d reactive. CD1d was expressed by 80-100% of cells in three of seven acute myeloid leukemias (AMLs) and by 28-77% of cells in five of six juvenile myelomonocytic leukemias (JMML). CD1d + AML cells were myelomonocytic or monoblastic types, and CD1d + JMML cells were differentiated and CD34 À . Cytotoxicity required leukemia cell CD1d expression and was increased by aGalCer (Po 0.0001) and inhibited by anti-CD1d mAb (Po 0.001). The perforin/granzyme-B pathway of NKT cells caused up to 85% of cytotoxicity, and TNF-a, FASL, and TRAIL mediated additional killing. CD56 + NKT cells expressed greater perforin and were more cytotoxic than CD56 NKT cells without aGalCer (Po 0.0001), but both subpopulations were highly and equally cytotoxic in the presence of aGalCer. We conclude that CD1d expression is stage-specific for myelomonocytic leukemias and could provide a target for NKT-cell-mediated immunotherapy.
Introduction a-Galactosyl-ceramide (aGalCer, KRN7000) reactive natural killer T (NKT) cells are an evolutionarily highly conserved sublineage of T-cells that express an invariant T-cell receptor (TCR) a-chain (Va24JaQ) and that often express the NK cell marker CD161. The development and effector functions of NKT cells depend upon recognition of a non-polymorphic HLA class I-like molecule, CD1d. [1] [2] [3] [4] aGalCer, a glycosphingolipid derived from the marine sponge Agelas mauritanius, binds CD1d, and the aGalCer/CD1d complex is recognized with high affinity by the NKT cell TCR. [5] [6] [7] [8] aGalCer elicited potent antitumor responses in murine models 9 and had low toxicity in cancer patients in a phase I clinical trial. 10 Several normal and malignant human hematopoietic cell types express CD1d on their surface. These include normal monocytic-lineage cells (monocytes, macrophages, dendritic cells), [11] [12] [13] [14] myelomonocytic leukemia cell lines U937, 15 and KY, 16 and malignancies originating from Langerhans cells or interdigitating dendritic cells.
14 CD1d also is expressed by thymocytes 12 and by T-cell leukemia cell lines Jurkat and MOLT-4. 15, 17 Thus, CD1d expression by hematopoietic and leukemia cells is not lineage restricted, but little is known about differentiation stage specificity.
Although initial studies indicate that NKT cells can be directly cytotoxic against leukemia cells, 15, [17] [18] [19] [20] questions about CD1d restriction, effector cell phenotype, cytotoxic mechanisms, and the role of aGalCer remain. Short-term cytotoxicity of NKT cells against leukemia targets has been reported to be CD1d restricted 15, 20 or not. 17, 19 It is yet to be established whether primary myeloid leukemias express CD1d, and whether NKT cells can recognize it. CD4 and CD161 status of NKT cells was not associated with different cytotoxicity, and other subsets have not been evaluated. 18 NKT cell cytotoxicity against leukemia cell lines has been reported to depend on perforin/granzyme-B alone 17, 18 or perforin/granzyme-B together with FAS ligand (FASL) and TNF-a. 20 In contrast, NKT cytotoxicity against primary myelomonocytic leukemia cells has been reported to be mostly because of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). 19 Finally, although pulsing CD1d + leukemia cell lines with aGalCer markedly increased NKT cell cytotoxicity, 15 it has not been determined if this is the case for primary myeloid leukemia cells.
We report here that NKT cell cytotoxicity against primary myelomonocytic leukemia cells requires target cell CD1d and is primarily mediated by perforin/granzyme-B. CD56 + NKT cells more frequently express perforin and are more cytotoxic than CD56
À NKT cells in the absence of aGalCer, whereas both subsets are equally and highly cytotoxic for leukemia cells that are pulsed with aGalCer. CD56 + but not CD56
À NKT cells in blood of normal individuals frequently express perforin.
Materials and methods

Patient samples and cell lines
Bone marrow or peripheral blood (juvenile myelomonocytic leukemia, JMML only) samples were collected from 14 patients with leukemia at diagnosis in clinical protocols approved by the respective Institutional Review Boards. Clinical and diagnostic laboratory data for the patients are presented in Table 1 . The samples were cryopreserved in aliquots of 10-20 Â 10 6 cells. At the time of analysis, cells were thawed and placed for 1 h in thawing medium containing RPMI 1640 with 30% fetal calf serum (FCS; Gemini-Bio-Products, Inc, Calabasas, CA, USA), 2 mM L-glutamine (Irvine Scientific, Santa Ana, CA, USA), 50 U/ml penicillin G sodium, 50 mg/ml streptomycin sulfate (GibcoBRL Inc, Gaithersburg, MD, USA), 20 U/ml heparin (Elkins-Sinn, Inc, Cherry Hill, NJ, USA), and 20 mg/ml Dnase-I (Qiagen Gmbh, Hilden, UK). Cells were washed twice and incubated overnight in complete RPMI 1640 medium containing 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin G sodium, and 50 mg/ml streptomycin sulfate in the presence of 100 ng/ml aGalCer (provided by Kirin Brewery Co., Ltd., Tokyo, Japan) or 0.1% DMSO (Sigma-Aldrich Co, St Louis, MO, USA) as a vehicle control. All experiments were performed during the day following overnight culture. The myelomonocytic leukemia cell line U937 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in complete RPMI 1640 medium prepared as above.
Cell surface phenotype of leukemia cells
CD1d surface expression was determined by indirect immunofluorescence using anti-CD1d mAb 42.1 (Dr S Porcelli, Albert Einstein College of Medicine, Bronx, NY, USA). PE-goat antimouse IgG (H+L) and mouse IgG1 mAb 679.1Mc7 (BeckmanCoulter, Miami, FL, USA) were used for detection and isotype control, respectively. Additional surface markers on JMML cells were detected using directly conjugated mAbs: FITC-anti-CD14 RM052 (Beckman-Coulter), Cy-Chrome-anti-CD34 581, Cy-Chrome anti-CD64 10.1 (PharMingen, La Jolla, CA, USA). Fc-receptor binding of the mAbs was excluded by blocking with 100% human serum (Sigma-Aldrich). Flow-cytometry analysis was performed with a Coulter s EPICS s Elite flow cytometer (Beckman-Coulter).
NKT cell lines
NKT cell lines from two donors were obtained and maintained as previously described with minor modifications. 15 Briefly, venous blood, collected from healthy adult volunteers, was obtained after informed consent. Peripheral blood mononuclear cells (PBMC) were cultured in complete RPMI 1640 medium in the presence of 50 ng/ml aGalCer (Kirin) and 50 U/ml IL-2 (R&D Systems Inc, Minneapolis, MN, USA) added every 3 days. On day 7, NKT cells were positively selected using PE-aGalCer/ CD1d tetramers (provided by Dr Mitchell Kronenberg, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA) and anti-PE MACS beads (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's protocol. Isolated NKT cells were cultured in complete RPMI 1640 medium supplemented with 50 U/ml IL-2 and were restimulated every 10 days for 24 h with IL-2 and fluorochrome-free aGalCer/CD1d tetramers coated onto six-well plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA; 17 mg/well tetramer in 3 ml PBS was incubated overnight at 41C and washed three times with PBS immediately before adding the cells).
Cell surface phenotype was analyzed by flow cytometry with multicolor immunofluorescence using the following mAbs: FITC-and PE-anti-Va24 C15, PE-anti-Vb11 C21 (BeckmanCoulter); Cy-Chrome-anti-CD3 UCHT1, FITC-anti-CD4 RPA-T4, PE-anti-CD8 HIT8a, PE-anti-CD161 DX12, PE-anti-CD56 B159, PE-anti-CD94 HP-3D9, PE-anti-CD16 3G8 (PharMingen, San Diego, CA, USA); FITC-anti-JaQ 6B11 (kindly provided by Dr Brian Wilson, Harvard University, Boston, MA, USA). The phenotype of the NKT cell lines is shown in Table 2 . Anti-CD56 MACS beads (Miltenyi Biotech) were used to sort for CD56 + and CD56 À NKT cells. The intracellular expression of perforin, TNFa, FASL, and TRAIL was examined by flow cytometry using direct and indirect immunofluorescence. NKT cells that had been cultured with IL-2 alone for 7 days after tetramer restimulation were analyzed before and after incubation for 6 h on tetramer-coated plates. The cells were fixed and permeabilized with Cytofix/Cytoperm TM (PharMingen) accord- 
Analysis of peripheral blood NKT cells
Neutravidin and neutravidin-CyC (-PE, or -FITC) (Molecular Probes Inc, Eugene, OR, USA) were used to tetramerize and fluorochrome label (CY-C, PE, or FITC) biotin-labeled a-GalCer/ CD1d and DMSO mock/CD1d monomers (Dr M Kronenberg). After magnetic bead depletion of CD14 + cells, tetramer binding was performed in 100% human serum (Sigma-Aldrich) with cells preincubated (15 min, room temperature) with neutravidinmock/CD1d tetramers to reduce nonspecific binding. Fluorochrome mock/CD1d tetramers were used for negative control. Up to 10 6 events per sample were collected. After gating on tetramer-positive cells, cell surface and/or intracellular antigens of NKT cells were detected using fluorochrome-conjugated mAbs as above. ) in 100 ml complete RPMI 1640 medium in duplicate wells of a 96-well plate. After 6 h, 60 ml of cell-free supernatant (after centrifugation) was collected from each well and frozen at À801C until cytokine analysis. Cytokines were detected with the CBA kit (PharMingen) according to the manufacturer's manual and as we previously described. 15 Briefly, CBA utilizes a series of beads with discrete fluorescence intensity at 670 nm. Each series of beads is coated with a mAb against a single cytokine (IL-2, IL-4, IL-5, IL-10, IFN-g, or TNF-a) and the mixture of beads detects six cytokines in one sample. A secondary PEconjugated mAb stains the beads proportionally to the amount of bound cytokine. After fluorescence intensity calibration and electronic color compensation procedures, standard and test samples were analyzed with a Coulter s EPICS s Elite flow cytometer. The argon laser at 488 nm excited fluorescence, and emitted light was measured at 670 and 576 nm. Data were analyzed using EXPO TM 32 Analysis software (BeckmanCoulter).
Cytometric bead array (CBA) analysis
Cytotoxicity assays
Target cell viability was measured by quantifying retained calcein-AM fluorescence with Digital Image Microscopy Scanning (DIMSCAN) as previously described. 21, 22 Immediately before adding calcein-AM, dead cells were depleted from leukemia cell preparations by gradient centrifugation, and CD56 + cells (if detectable) were removed by anti-CD56 MACS beads (Miltenyi Biotech) to exclude the possibility of NK cell cytotoxicity. Calcein-AM (Molecular Probes Inc.) was added to the target cells, 5 mg/ml (1 mg/ml for flow cytometry), and the cells were incubated at 371C for 30 min. After washing, labeled target cells (10 4 cells in 50 ml per well) were plated into 96-well Falcon 3072 microtiter plates (Becton Dickinson Inc, Franklin Lakes, NJ, USA). Purified NKT cells that had been restimulated with aGalCer/CD1d tetramers and IL-2, washed, and then cultured for 7 days with IL-2 alone were washed and added in 50 ml per well at the desired effector to Target (E: T) ratio. Each plate included six wells of target cells alone as control.
Plates were incubated at 371C in a humidified atmosphere with 5% CO 2 for 6 h and then analyzed by DIMSCAN. Data were expressed as cytotoxicity, % (cytotoxicity, % ¼ mean fluorescence intensity in six control wellsÀfluorescence intensity in experimental well/mean fluorescence intensity in six control wells) Â 100. The mean cytotoxicity, %7s.d. for each condition was calculated from six replicate experimental wells.
Alternatively, NKT cell cytotoxicity was measured by flow cytometry using three replicate microwells. As above, NKT cells were used 7 days after tetramer restimulation. Target cells were identified as the calcein-AM + population (killed calcein-AMstained target cells are at least 10-fold more fluorescent than unstained NKT cells). After gating on target cells, cytotoxicity was calculated as the percent increase of the calcein-AM low population relative to target cells alone (cytotoxicity, % ¼ (cal-(calcein-AM low in experimental wellsÀcalcein-AM low in control wells)/calcein-AM high in control well Â 100). The mean cytotoxicity %7s.d. for each condition was calculated from three replicate experimental wells.
Blocking NKT cell cytotoxicity
To inhibit perforin containing granules, NKT cells were preincubated with 100 nM concanamycin A (CMA) or with 0.1% DMSO (vehicle control) for 2 h. 23 The role of other cytotoxic molecules (TNF-a, TRAIL, and FASL) was evaluated by adding the appropriate neutralizing mAb or a mAb combination in addition to CMA (or without CMA when indicated), similar to a blocking procedure that was described for NK cells. 24 The following neutralizing mAbs were used: anti-TNF-a MAb-1, 10 mg/ml; anti-TRAIL RIK-2, 10 mg/ml (PharMingen); anti-FAS ZB-4, 1 mg/ml (MBL Co, Ltd, Watertown, MA, USA); and antiCD1d 42.1, 50 mg/ml (S Porcelli). Target cell killing was evaluated after incubation for 6 h using the calcein-AM flowcytometry assay as described above.
Oligonucleotide array expression analysis of NKT cells
Quiescent NKT cells, which had not been stimulated with tetramers for 7 days, were re-stimulated on tetramer-coated plates for 6 h. Total RNA was precipitated from duplicate stimulated and unstimulated cultures (15 Â 10 6 cells per culture) using TRIzol s (Invitrogen Co., Carlsbad, CA, USA) and then further purified with the RNeasy Mini kit (Qiagen Corp., Valencia, CA, USA). Double-stranded cDNA was synthesized from total RNA using HPLC purified T7-(dT) primer (5 0 -GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT) 24 -3 0 ; GENSET, La Jolla, CA, USA), and purified using phase lock gels -phenol/chloroform extraction and ethanol precipitation. Biotin-labeled cRNA was synthesized from cDNA (in vitro transcription) using the ENZO Bioarray High Yield RNA Transcript Labeling kit (Affymetrix, Santa Clara, CA, USA) and was purified with QIAGEN RNeasy columns and ethanol precipitation. After quantification with a spectrophtometer, cRNA was fragmented and hybridized to Affymetrix U95AV2 Arrays, and arrays were washed and scanned according to manufacturer instructions (Affymetrix). Data from Affymetrix.cel files were preprocessed using dChip software to normalize arrays, calculate model-based expression values, and identify probe and array outliers. 25 Genetrix software was used to visualize gene expression levels and to provide values for further analysis.
Data analyses
Flow-cytometry data were analyzed with EXPO TM 32 Analysis software (Beckman-Coulter). Analysis of DIMSCAN data used Excel (Microsoft Corp., Redmond, WA, USA) to calculate the tumor cell viability % (mean7s.d. for six replicate wells; see above). SigmaPlot 4.0 (Jandell Scientific, San Rafael, CA, USA) was used to create graphs, and GraphPad Prism TM (GraphPad Software, San Diego, CA, USA) was used to perform t-tests or one-way ANOVA with the Tukey-Kramer post-test comparison of group means. Correlation was analyzed by the Pearson test. Significance was accepted when Po 0.05.
Results
CD1d expression by primary leukemia cells
CD1d expression was examined on leukemia cells that were cryopreserved from seven AML, one CML, and six JMML patients (Table 1) . Three CD1d + AML with a level of expression similar to that of normal blood monocytes and the myelomonocytic leukemia cell line U937 were either myelomonocytic M4-type (patients 5 and 6) or monoblastic M5-type (patient 7) (Figure 1 ; Table 1 ). Four AML samples with less mature blasts (M1-M3 types) and CML cells with nonmonocytic differentiation expressed little or no CD1d (Table 1) .
Blood samples from five of six patients with JMML, a chronic myelomonocytic leukemia that originates from a pluripotent progenitor and tends to differentiate towards monocytic cells, 26, 27 contained increased frequencies of CD1d + cells
Figure 1
CD1d expression by leukemia cells. CD1d surface expression was examined for normal blood monocytes, the U937 myelomonocytic leukemia cell line, and leukemia specimens from patients (see Table 1 ) by indirect immunofluorescence using anti-CD1d mAb 42.1 and PE-anti-mouse IgG1. Data are presented as overlapping histograms: isotype control, open dotted histograms; CD1d, solid-filled histograms. Normal blood monocytes were identified using forward and side scatter parameters. Data represent one of at least three independent experiments for normal monocytes, U937 cells, or patient samples that provided similar results. 
Specific target recognition and cytokine production by NKT cells
To evaluate requirements for target recognition by NKT cells, we used CBA to detect production of five cytokines (IL-4, IL-5, IL-10, TNF-a, and IFN-g) by NKT cells during a 6-h coculture with leukemia targets pulsed or not with aGalCer. Recombinant IL-2 was present in the cultures. Resting NKT cells alone (7 days after restimulation with aGalCer/CD1d tetramers and IL-2 for 24 h) produced small amounts of IL-5 (34.0712.4 pg/ml) but not detectable amounts of other cytokines. NKT cells that were cocultured with AML M4 leukemia cells (patient 6) produced TNF-a (38.2715.5 pg/ml) and IL-4 (21.678.1 pg/ml), whereas those cocultured with the same cells pulsed with aGalCer produced IL-4 (1262.77305.4 pg/ml), IL-5 (739.67243.0 pg/ml), TNF-a (5371.87682.1 pg/ml), and IFN-g (3718.97425.3 pg/ml) but not IL-10 ( Figure 3) . Similar profiles and levels of cytokines were induced by NKT cells cultured with AML, M5 (patient 7), and JMML cells (patients 10 and 13) (data not shown). CD1d-leukemia cells did not induce cytokine production by NKT cells in the absence or presence of aGalCer, and aGalCer alone (in the absence of target cells) was ineffective (data not shown). Thus, NKT cells specifically recognize ligands presented by CD1d of myelomonocytic leukemia cells.
NKT cell cytotoxicity against leukemia cells
We tested NKT cell cytotoxicity against CD1d-positive and -negative leukemia cells using digital image microscopy scanning to detect loss of fluorescence from calcein-AM-labeled target cells after 6 h. NKT cell cytotoxicity strongly correlated with the level of CD1d expression on myeloid leukemia cells from 14 tested samples in the absence (R 2 ¼ 0.85, Po 0.0001; Pearson's correlation test) and even more so in the presence of aGalCer (R 2 ¼ 0.96, Po 0.0001) (Figure 4 ). All three CD1d-positive myelomono-or monoblastic AML samples that were tested were sensitive to NKT cells with 14.875.2-28.474.3% (without aGalCer) and 47.276-74.976.2% (with aGalCer) of cells being killed. JMML cells from two tested samples with more than 50% CD1d + cells also were killed (cytoxicity was 12.5-28.2% without and 42.8-71.2% with aGalCer). Cytotoxicity of NKT cells against CD1d-negative myeloid leukemia cells did not exceed 5% in the absence or presence of aGalCer.
Gene expression of cytotoxic molecules by NKT cells
To evaluate expression of genes that may have a role in NKT cell cytotoxicity, oligonucleotide microarray analysis was performed on the same NKT cells used for cytotoxicity testing before and 6 h after their stimulation with aGalCer/CD1d tetramers. This timing was employed to coincide with that of cytotoxicity tests and with cytokine production, which is near maximum at 6 h. 15 Additionally, NKT cell functional responses in mice are rapid.
28,29 Figure 5 demonstrates expression of cytotoxicityrelated genes derived from data generated with Affymetrix U95AV2 oligonucleotide arrays. Even without TCR stimulation, perforin and granzymes are expressed at high levels, whereas TNF-a, FASL, and TRAIL are expressed at very low levels. TCR stimulation resulted in significant upregulation of granzyme-B (P ¼ 0.001) as well as TNF-a (P ¼ 0.0007), FASL (P ¼ 0.002), and TRAIL (P ¼ 0.02). Even after stimulation, expression of granzyme-B and perforin remained four-to six-fold and two to threefold higher, respectively, than that of TNF-a, FASL, and TRAIL. These changes in perforin and TNF family ligands following stimulation of NKT cell TCR were confirmed by intracellular flow cytometry (data not shown). 
Mechanism of NKT cell cytotoxicity
To examine the cytotoxic pathways utilized by NKT cells against primary myelomonocytic leukemia cells, we used CMA to neutralize perforin and neutralizing mAbs against TNF-a, FAS receptor, and TRAIL alone or in combination (Figure 6a ). At the highest tested effector to target ratio of 25:1, CMA decreased NKT cell cytotoxicity from 28.471.6 to 13.571.3% (Po 0.001, ANOVA) in the absence of aGalCer and from 74.771.6 to 24.571.0% (Po 0.0001, ANOVA) in the presence of aGalCer. Remaining cytotoxicity was further reduced by combining CMA and anti-TNF-a mAb, and was completely abolished by combining CMA with anti-TNF-a, anti-FAS, and anti-TRAIL mAbs in the absence or presence of aGalCer (Po 0.05). Inhibitory effects of anti-FAS or anti-TRAIL mAbs alone were minimal (data not shown). Since TRAIL was reported to be responsible for approximately 80% of NKT cytotoxicity against M4 leukemia cells in the absence of aGalCer and this cytotoxicity was the highest between 3 and 7 days after restimulation of NKT cells by aGalCer pulsed dendritic cells, 19 we tested our purified NKT cells at 2, 4, 6, 8, and 10 days after restimulation with aGalCer/CD1d tetramers and IL-2 and found that anti-TRAIL blocking mAb alone decreased cytotoxicity by only 5-15% at all times in the presence or absence of aGalCer (not shown). Thus, our experiments with highly purified NKT cells indicate that the Cytokine production by NKT cells in response to aGalCer presented by leukemia targets. NKT cells that had been cultured with IL-2 alone for 7 days after tetramer restimulation were cultured for 6 h alone or with leukemia cells from patient 6 that were pulsed overnight with 0.1% DMSO (vehicle control) or with 100 ng/ml aGalCer. The indicated cytokines were measured in the supernatants using CBA as described in Methods. The cytokine concentration is proportional (in the range 20-5000 pg/ml) to the fluorescence intensity at 576 nm (X-axis), and is provided in Results. Data are from one of four experiments with two NKT cell lines that provided similar results. Table I ) were pulsed overnight with 100 ng/ml aGalCer or 0.1% DMSO (vehicle control), stained with calcein-AM, and incubated for 6 h with NKT cells that had been cultured with IL-2 alone for 7 days after tetramer restimulation (E:T ratio 10:1). NKT cell cytotoxicity was determined with the digital image scanning microscopy (DIMSCAN) assay as described in Methods. The mean7s.d. cytotoxicity percentage for six replicate wells (Y-axis) are plotted against the percentage of CD1d expression in corresponding samples (X-axis). The percentage of leukemia and CD1d + cells in each specimen is provided in Table 1 . 
Distribution of perforin expression in NKT cell subpopulations
Since perforin and granzyme-B were mainly responsible for NKT cell cytotoxicity, we examined perforin expression in noncultured and cultured NKT cells and determined the relationship to CD4 and CD56 expression. The latter was evaluated because perforin has been reported to be mostly expressed by CD4 À blood NKT cells, 30 and because CD56 + cytotoxic T lymphocytes have increased levels of perforin. 31 We found that 24.877.6% (n ¼ 7) of uncultured NKT cells express CD56 and 12.3-79.8% of them expressed perforin. In contrast, perforin was detected in only 0-5.3% of CD56 À NKT cells. A representative experiment demonstrates that CD56 + NKT cells contain a perforin expressing subset, which represents 90% of perforin-positive cells in uncultured NKT cells (Figure 7 ). Like perforin, CD56 was mostly expressed by CD4 À NKT cells. After 7 days of culture, the frequency of perforin expression increased in both CD56 + and CD56 À NKT cells, but CD56 + cells still expressed perforin 4.1-fold more often than CD56
À cells. Both markers were equally Cytotoxic pathways utilized by NKT cells against leukemia cells. NKT cells that had been cultured with IL-2 alone for 7 days after tetramer restimulation were coincubated for 6 h with AML M4 cells from patient 6 that had been pulsed overnight with 0.1% DMSO or with 100 ng/ml aGalCer. (a) NKT cells were preincubated for 2 h with 0.1% DMSO or mouse IgG1 isotype control mAb (controls) or with 100 ng/ml CMA alone or with anti-TNF-a and/or anti-TRAIL neutralizing mAb(s). Target cells were pre-incubated for 1 h with anti-FAS blocking mAb where indicated. (b) Target cells were incubated with 50 mg/ml anti-CD1d blocking mAb 42.1 or isotype control mAb for 1 h before and then during the 6 h cytototoxicity test with NKT cells. Effector to target ratios from 0.5:1 to 25:1 were tested, and cytotoxicity was measured after 6 h by flow cytometry. Data are mean7s.d. for triplicate wells from one of three independent experiments with two NKT cell lines that provided similar results (note that s.d. for each data point was o2%, and so s.d. bar is obscured in many instances by the data point). 
CD56 expression and NKT cell cytotoxicity
In vitro expanded NKT cells were sorted for CD56 + and CD56 À subpopulations with 99.2 and 98.4% CD56 positive and negative, respectively, and cytotoxicity of the sorted cells was tested against AML M4 cells pulsed or not with aGalCer ( Figure 8 ). CD56 + cells were significantly more cytotoxic than CD56 À cells against AML M4 cells in the absence of aGalCer (Po 0.001, ANOVA). However, both subpopulations mediated greater and equally strong cytotoxicity when target cells were pulsed with aGalCer. Cytotoxicity of CD56 + and CD56 À NKT cell subsets was CD1d restricted, since the anti-CD1d blocking mAb significantly decreased killing by both subsets (Po 0.0001, and P ¼ 0.019, respectively, ANOVA; Figure 8 ) similar to its effect on killing by the total NKT cell population (Figure 6b ).
Discussion
This study demonstrated for the first time that myelomonocytic leukemia cells from patients with M4 or M5 AML or with JMML express CD1d as a stage-specific differentiation antigen. We also show that NKT cells only recognize and kill CD1d + , but not CD1d À , myeloid leukemia cells, and that the cytotoxicity is strongly augmented by aGalCer. Gene expression analysis revealed that cultured NKT cell lines constitutively express high levels of perforin and granzyme mRNA and that these further increase 6 h after TCR stimulation. In contrast, high expression of TNF-a, FASL, and TRAIL mRNA only occurs after TCR stimulation. Up to 85% of NKT cell cytotoxicity against primary CD1d + leukemia cells in a 6 h assay is mediated by perforin/ granzyme-B, and this is augmented by TNF-a, FASL, and TRAIL. We provide evidence that CD56 expression is associated with increased frequency of perforin expression in both cultured and noncultured NKT cells. Cytotoxicity of both CD56 + and CD56 À subpopulations of NKT cells is CD1d dependent. CD56 + NKT cells mediate greater cytotoxicity against CD1d + leukemia cells in the absence of aGalCer, but both NKT cell subsets are highly cytotoxic in the presence of aGalCer.
CD1d was uniformly expressed by all the three samples of AML with monocytic differentiation (M4, M5) but not by four AML specimens with less differentiation (M1-M3). This is consistent with CD1d expression by monocytes 13 and myelomonocytic leukemia cells lines U937 15 and KY and not by less differentiated myeloid leukemia cell lines Kasumi (M2), NB4 (M3), and HL-60 (M3). 16 There are inconsistencies in the literature regarding CD1d expression by U937 cells and their susceptibility to NKT cell cytotoxicity. 15, 17, 20 This could be explained by different sources of U937 cells and/or by their loss of CD1d expression and susceptibility to NKT cell cytotoxicity in culture (LS Metelitsa, unpublished observations). Analysis of JMML cells revealed that CD1d is expressed by progenitors of monocyte-like leukemia cells after loss of CD34 and before and after acquisition of CD14 and CD64. Taken together, our data for AML and JMML indicate that CD1d is a stage-specific differentiation antigen for myelomonocytic/monocytic leukemias. Although CD1d expression is not limited to myeloid tissue, 12 it may be of value for defining a stage of leukemia cell differentiation in AML and JMML.
Primary leukemia cells obtained from patients with AML (M4, M5) and JMML, which express CD1d, effectively presented aGalCer and specifically induced cytokine production and cytotoxicity by NKT cells. In agreement with our previous observations 15 and another recent report, 20 NKT cells were not cytotoxic against CD1d-negative leukemia cells. Susceptibility of AML M4 leukemia cells to NKT cell cytotoxicity has been reported, 19 although expression of CD1d by the leukemia cells was not examined and aGalCer was not tested. Together, our data and the previous report 19 agree that myelomonocytic and monoblastic AML (M4, M5), but not less differentiated AML (M1-M3), cells are susceptible to NKT cell cytotoxicity. Our study demonstrates the importance of CD1d and aGalCer for maximal NKT cell cytotoxicity.
Oligonucleotide array expression analysis of genes involved in cytotoxicity demonstrated that in vitro expanded NKT cells constitutively express very high levels of mRNA for perforin and granzymes. In the absence of TCR stimulation, genes of TNFfamily cytotoxic molecules (TNF-a, FASL, and TRAIL) were expressed at very low levels. This suggests that early after target cell recognition, NKT cell cytotoxicity is mostly because of the perforin/granzyme-B system. Transcription of TNF-family ligands was increased up to 11-fold 6 h following TCR stimulation, suggesting that these molecules, after upregulation, also may contribute to cytotoxicity. Our experiments are consistent with studies that found expression of perforin, granzyme-B, TNF-a, FASL, and TRAIL in human NKT cells, 20, [32] [33] [34] and additionally, they show that transcription of this combination of cytotoxicity-related genes rapidly increases following stimulation of NKT cell TCR.
NKT cell cytotoxicity against myeloid leukemia cells was CD1d restricted since it was absent against CD1d-negative leukemia cells, augmented by aGalCer, and inhibited by antiCD1d blocking mAb 42. + and CD56-subpopulations using anti-CD56 magnetic beads. AML M4 cells (patient 6) were pulsed overnight with 100 ng/ml aGalCer or 0.1% DMSO and then incubated with 50 mg/ml anti-CD1d blocking mAb 42.1 or isotype control mAb for 1 h before and during the 6 h cytototoxicity test with NKT cells. Cytotoxicity of CD56 + and CD56 À NKT cells was tested using flow cytometry as described in Figure 4 . Data are mean7s.d. for triplicate wells from one of three independent experiments with two NKT cell lines that provided similar results (s.d. for each data point was o2%).
NKT Cells kill CD1d
+ myeloid leukemia cells LS Metelitsa et al mechanisms, including perforin/granzyme-B, TNF-a, FASL, and TRAIL but that nearly all cytotoxicity depends on perforin/ granzyme-B regardless of time after TCR stimulation. In contrast to our results, Nieda et al 19 reported NKT cell cytotoxicity against AML M4 cells to mostly depend on TRAIL and to be CD1d independent. 19 However, it is difficult to compare the two studies since experimental conditions were quite different. We used purified total NKT cells ( Although the greatest NKT cell cytotoxicity occurred against aGalCer-pulsed target cells, we and others observed cytotoxicity against CD1d + U937 and AML M4 cells in the absence of aGalCer. 15, 17, 19 This suggests that the leukemia cells express a natural CD1d-bound ligand for NKT cells, which is yet to be identified. The hypothetical natural ligand(s) may be less agonistic for NKT cell TCR compared to aGalCer resulting in weaker cytotoxic response. Despite the difference in the amplitude of killing, however, there was no difference in the mechanism of NKT cell cytotoxicity in the presence or absence of aGalCer.
We demonstrate for the first time that perforin expression is more frequent in CD56 + than in CD56 À NKT cells both before and after in vitro culture. Perforin was detected in CD56 + but infrequently in CD56
À blood NKT cells, and its expression was greatly increased in both CD56 + and CD56 À cells after culture with aGalCer and IL-2. In agreement with a recent report, 30 noncultured peripheral blood NKT cells mostly expressed perforin and CD56 in CD4 À NKT cells, but cultured NKT cells expressed perforin and CD56 equally in both CD4 + and CD4 À cells. Consequently, there was no difference in cytotoxicity between in vitro expanded CD4 + and CD4 À NKT cells (data not shown), which is consistent with a previous report.
18 CD56 + NKT cells, however, were significantly more cytotoxic than CD56 À cells against AML M4 cells in the absence of aGalCer. Therefore, CD56 expression defines a subset of NKT cells with high cytotoxic activity and may be used to monitor cytotoxic potential of peripheral blood NKT cells. This also may be applied for ex vivo enrichment of cytotoxic NKT cells for adoptive immunotherapy. Correlation between CD56, perforin expression, and cytotoxic activity has also been observed for conventional CD8 + cytotoxic T lymphocytes, 31, 35 reflecting functional similarities for these two sublineages of T cells. Of importance, our data demonstrated that cytotoxicity of CD56 + NKT cells remained CD1d restricted.
Our data suggest that NKT cells, especially with aGalCer, should be considered for specific immunotherapy of CD1d-positive AMLs. Additionally, even though poorly differentiated JMML stem cells do not express CD1d, targeting the CD1d positive monocyte-like subpopulation with aGalCer could be a component of multiagent therapy. However, the low frequency of NKT cells in blood, although not necessarily reflecting their potential for localizing to sites of malignant cells, suggests that expanding the pool size would be desirable. aGalCer alone may not be sufficient since the number of blood NKT cells in mice does not increase following injection of aGalCer. 28 Since human NKT cells rapidly proliferate in vitro when both aGalCer and IL-2 are employed, this combination could be considered for in vivo expansion while monitoring NKT cell proliferation, differentiation, and apoptosis. Alternatively, adoptive immunotherapy could be tested using NKT cells prepared by ex vivo expansion with aGalCer and IL-2, 34, 36 which is feasible with cells from both normal and leukemic donors. 17, 19 The use of NKT cells from normal donors, which are able to kill allogeneic targets because CD1d is nonpolymorphic, would avoid the risk of reinfusing leukemia cells that might contaminate autologous NKT cell preparations. Such strategies, however, may not be without toxicities, since NKT cells could destroy normal CD1d expressing cells (e.g., monocyte-derived dendritic cells) and could produce cytokines (e.g., TNF-a, IFN-g, IL-2) in quantities sufficient to have systemic effects.
